Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dare Bioscience Inc

DARE
Current price
2.99 USD -0.015 USD (-0.50%)
Last closed 3.01 USD
ISIN US23666P1012
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 26 551 170 USD
Yield for 12 month -11.76 %
1Y
3Y
5Y
10Y
15Y
DARE
21.11.2021 - 28.11.2021

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. Address: 3655 Nobel Drive, San Diego, CA, United States, 92122

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.33 USD

P/E ratio

Dividend Yield

Current Year

+9 784 USD

Last Year

+2 807 885 USD

Current Quarter

-63 647 USD

Last Quarter

+41 691 USD

Current Year

+9 784 000 USD

Last Year

+2 769 522 USD

Current Quarter

-63 647 USD

Last Quarter

+41 691 USD

Key Figures DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -23 409 160 USD
Operating Margin TTM 8 465.75 %
Price to Earnings
Return On Assets TTM -67.57 %
PEG Ratio
Return On Equity TTM -994.69 %
Wall Street Target Price 13.33 USD
Revenue TTM 9 784 USD
Book Value -0.69 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -95.80 %
Dividend Yield
Gross Profit TTM -14 295 424 USD
Earnings per share -0.48 USD
Diluted Eps TTM -0.48 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics DARE

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:12
Payout Ratio TTM
Last Split Date 01.07.2024

Stock Valuation DARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1 242.44
Price Sales TTM 2 713.73
Enterprise Value EBITDA -2.06
Price Book MRQ 10.75

Financials DARE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DARE

For 52 weeks

2.67 USD 7.56 USD
50 Day MA 2.98 USD
Shares Short Prior Month 87 442
200 Day MA 3.30 USD
Short Ratio 3.05
Shares Short 62 355
Short Percent 0.71 %